Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Purpose: To describe the frequency and severity of ototoxicity in a series of pediatric patients treated with platinum-based chemotherapy. Patients and Methods: Serial audiologic evaluations were conducted for 67 patients aged 8 months to 23 years who received platinum-based chemotherapy. Audiologic data was analyzed to determine time to hearing-loss using American Speech-Language-Hearing Association (ASHA) criteria, and the effects of treatment and patient characteristics on the incidence and severity of ototoxicity. Results: Bilateral decreases in hearing were seen in 61% of patients (median time to hearing loss, 135 days). Children treated for medulloblastoma, osteosarcoma, and neuroblastoma had greater incidence and severity of hearing loss. Agreement between the usually reported National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and ASHA criteria was inadequate. Conclusion: Traditional reporting of toxicity data (CTCAE) has under-reported ototoxicity and minimized the significance of hearing loss in children. As pediatric patients experience improved survival, the effects and implications of high-frequency hearing loss with regard to academic achievement and speech and language development are important considerations, especially in patients younger than 5 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors Governing the Intelligibility of Speech Sounds
French, N. R., & Steinberg, J. C. (1947) · The Journal of the Acoustical Society of America · doi:10.1121/1.1916407 · Cited by 1,131
Bess, F. H., Dodd-Murphy, J., & Parker, R. A. (1998) · Ear and Hearing · doi:10.1097/00003446-199810000-00001 · Cited by 847 · cited 1×
“academic difficulties and social-emotional problems, and increased levels of fatigue in the learning environment.(20) To properly build their language foundation, children must be able to hear all of the sounds of speech.”
BackgroundNorthern, J. L., & Downs, M. P. (1974) · Cited by 432
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose
Li, Y., Womer, R. B., & Silber, J. H. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.08.009 · Cited by 358
Speech recognition with reduced spectral cues as a function of age
Eisenberg, L. S., Shannon, R. V., Martinez, A. S., Wygonski, J. J., & Boothroyd, A. (2000) · The Journal of the Acoustical Society of America · doi:10.1121/1.428656 · Cited by 312
Bertolini, P., Lassalle, M., Mercier, G., Raquin, M. A., Izzi, G., Corradini, N., & Hartmann, O. (2004) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000141348.62532.73 · Cited by 305
d-Methionine provides excellent protection from cisplatin ototoxicity in the rat
Campbell, K. C. M., Rybak, L. P., Meech, R. P., & Hughes, L. (1996) · Hearing Research · doi:10.1016/s0378-5955(96)00152-9 · Cited by 240
Dickey, D. T., Wu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087601 · Cited by 219
Self-citationThe Effects of Mild Sensorineural Hearing Loss on Academic Performance of Young School-Age Children.
Blair, J. C. (1985) · The Volta Review · Cited by 136
Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model
Dickey, D. T., Muldoon, L. L., Kraemer, D. F., & Neuwelt, E. A. (2004) · Hearing Research · doi:10.1016/j.heares.2004.02.007 · Cited by 130
Self-citation
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Mechanisms of cisplatin-induced ototoxicity and prevention
Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007) · Hearing Research · doi:10.1016/j.heares.2006.09.015 · Cited by 563
Change in Prevalence of Hearing Loss in US Adolescents
Shargorodsky, J. (2010) · JAMA · doi:10.1001/jama.2010.1124 · Cited by 494
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity
Karasawa, T., & Steyger, P. S. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.06.012 · Cited by 475
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Cisplatin is retained in the cochlea indefinitely following chemotherapy
Breglio, A. M., Rusheen, A. E., Shide, E. D., Fernandez, K. A., Spielbauer, K. K., McLachlin, K. M., Hall, M. D., Amable, L., & Cunningham, L. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01837-1 · Cited by 412
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
Brock, P. R., Knight, K. R., Freyer, D. R., Campbell, K. C. M., Steyger, P. S., Blakley, B. W., Rassekh, S. R., Chang, K. W., Fligor, B. J., Rajput, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1110 · Cited by 380
Self-citationSodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss
Brock, P. R., Maibach, R., Childs, M., Rajput, K., Roebuck, D., Sullivan, M. J., Laithier, V., Ronghe, M., Dall’Igna, P., Hiyama, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801109 · Cited by 380
Self-citationCisplatin Ototoxicity and Protection: Clinical and Experimental Studies
Rybak, L. P., Mukherjea, D., Jajoo, S., & Ramkumar, V. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.219.177 · Cited by 372
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
Sheth, S., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00338 · Cited by 361
Lannering, B., Rutkowski, S., Doz, F., Pizer, B., Gustafsson, G., Navajas, A., Massimino, M., Reddingius, R., Benesch, M., Carrie, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8719 · Cited by 333
the CPNDS Consortium, Ross, C. J. D., Katzov-Eckert, H., Dubé, M.-P., Brooks, B., Rassekh, S. R., Barhdadi, A., Feroz-Zada, Y., Visscher, H., Brown, A. M. K., et al. (2009) · Nature Genetics · doi:10.1038/ng.478 · Cited by 327
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Coccia, P. F., Pappo, A. S., Beaupin, L., Borges, V. F., Borinstein, S. C., Chugh, R., Dinner, S., Folbrecht, J., Frazier, A. L., Goldsby, R., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0001 · Cited by 295
Frisina, R. D., Wheeler, H. E., Fossa, S. D., Kerns, S. L., Fung, C., Sesso, H. D., Monahan, P. O., Feldman, D. R., Hamilton, R., Vaughn, D. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.8822 · Cited by 278
Drug‐induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies
Lanvers‐Kaminsky, C., Zehnhoff‐Dinnesen, A. A., Parfitt, R., & Ciarimboli, G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.603 · Cited by 277
Freyer, D. R., Chen, L., Krailo, M. D., Knight, K., Villaluna, D., Bliss, B., Pollock, B. H., Ramdas, J., Lange, B., Van Hoff, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30625-8 · Cited by 267
Self-citationMoke, D. J., Luo, C., Millstein, J., Knight, K. R., Rassekh, S. R., Brooks, B., Ross, C. J. D., Wright, M., Mena, V., Rushing, T., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00020-1 · Cited by 92
Self-citationMa, E., Chen, P., Wilkins, H. M., Wang, T., Swerdlow, R. H., & Chen, Q. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.008 · Cited by 79
Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer
Romano, A., Capozza, M. A., Mastrangelo, S., Maurizi, P., Triarico, S., Rolesi, R., Attinà, G., Fetoni, A. R., & Ruggiero, A. (2020) · Cancers · doi:10.3390/cancers12051266 · Cited by 65
Metadata
- Authors
- Knight, K. R. G., Kraemer, D. F., & Neuwelt, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-01
- Volume
- 23
- Issue
- 34
- Pages
- 8588-8596
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110043256
- Cited by
- 542
- References
- 15
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.